Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally
We recently compiled a list of the These 10 Firms Dominated Last Week’s Rally. In this article, we are going to take a look ...
ImmunityBio’s (IBRX) “Buy” Rating Reiterated at D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...
pharmaphorum23h
FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt
After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...
Dana (NYSE:DAN) Upgraded at UBS Group
UBS Group upgraded shares of Dana (NYSE:DAN – Free Report) from a neutral rating to a buy rating in a research report report ...